Core Viewpoint - Quantum BioPharma Ltd. announced that its subsidiary, Unbuzzd Wellness Inc., is launching a Regulation D 506(c) offering to raise up to US$5 million for growth and a potential initial public offering, which will not dilute Quantum BioPharma shareholders [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [6]. - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and has an agreement for royalty payments of 7% of sales from Unbuzzd until total payments reach US$250 million, after which the royalty rate drops to 3% [6]. Product Information - Unbuzzd is a beverage designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms, developed by a team with expertise in pharmacology and medicine [8][9]. - Clinical trials have shown that Unbuzzd can reduce blood alcohol concentration (BAC) by over 40% faster within 30 minutes compared to control subjects, improve alertness, and lessen hangover symptoms significantly [10][13]. Capital Raising Strategy - Unbuzzd has partnered with MZ Digital and Dealmaker to conduct the capital raise campaign, allowing investments through traditional and cryptocurrency payments [3]. - The offering aims to support direct-to-consumer, distributor, and retail expansion plans for Unbuzzd [5].

Core Viewpoint - Quantum BioPharma Ltd. announces that Unbuzzd Wellness Inc. is raising up to US$5 million through a Regulation D 506(c) offering to support its expansion plans for the unbuzzd™ beverage, which accelerates alcohol metabolism and reduces hangover symptoms [1][2][3] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, including alcohol misuse disorders [3] - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and is entitled to 7% royalty payments on unbuzzd™ sales until reaching $250 million, after which the royalty rate drops to 3% [3] Product Details - Unbuzzd™ is a scientifically-backed beverage designed to help alcohol consumers process alcohol faster, restore mental clarity, and alleviate hangover symptoms [5][6] - Clinical trials show that unbuzzd accelerates alcohol metabolism, reducing blood alcohol concentration (BAC) by over 40% faster within 30 minutes compared to control subjects [6][13] - Participants reported significant improvements in alertness and reductions in hangover symptoms, including a 67% reduction in headache severity at four hours post-consumption [13] Leadership and Strategy - John Duffy, CEO of Unbuzzd, emphasizes the commitment to providing a scientifically backed product to alcohol consumers and the importance of the capital raise for expansion [2] - Gerry David, Board Co-Chair, highlights that the capital raise will support company growth and position unbuzzd for a potential initial public offering [3]